Literature DB >> 21567111

Hyperbaric oxygen therapy reduces the toll-like receptor signaling pathway in multiple organ failures.

Barbara Rinaldi1, Salvatore Cuzzocrea, Maria Donniacuo, Annalisa Capuano, Donatella Di Palma, Francesco Imperatore, Emanuela Mazzon, Rosanna Di Paola, Loredana Sodano, Francesco Rossi.   

Abstract

PURPOSE: Zymosan-induced generalized inflammation is the only experimental model that reproduces characteristics of human multiple organ dysfunction syndrome (MODS). Toll-like receptors (TLRs) are key components in innate immune responses and their signaling pathway is known to activate target genes such as nuclear factor-κB (NF-κB) and cytokines that are involved in inflammation and immune responses. We previously reported that hyperbaric oxygen (HBO) therapy is effective in the treatment of severe zymosan-induced inflammation in MODS. The aim of this study was to investigate the effect of HBO exposure on TLR2 and TLR4 signal transduction and organ dysfunction during MODS induced by zymosan in the rat.
METHODS: Male Wistar rats were randomized into four groups and treated as follows: (1) saline solution (control); (2) zymosan; (3) HBO 4 and 11 h after zymosan injection; (4) HBO 4 and 11 h after saline solution injection. Zymosan-induced damage of the lungs, liver, and small intestine was evaluated using histology and biochemistry. The activation of the TLR signaling pathway was measured with Western blot, reverse transcriptase polymerase chain reaction analysis (RT-PCR), and immunohistochemistry.
RESULTS: Zymosan induced a severe inflammatory response characterized by the activation of the TLR signaling pathway and by an organ dysfunction. HBO exposure significantly reduced the development of lung, liver, and intestine injury in our experimental model. It also significantly reduced the zymosan-induced expression of TLR2 and TLR4, NF-κB activation, and cytokine production.
CONCLUSIONS: Taken together, these results suggest that, by interfering with the TLR pathway, HBO treatment may exert a protective effect against tissue injury caused by zymosan-induced generalized inflammation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567111     DOI: 10.1007/s00134-011-2241-1

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  39 in total

1.  Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-12-26       Impact factor: 41.582

Review 2.  Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors.

Authors:  Min-Fu Tsan; Baochong Gao
Journal:  J Endotoxin Res       Date:  2007

3.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product.

Authors:  K Hoshino; O Takeuchi; T Kawai; H Sanjo; T Ogawa; Y Takeda; K Takeda; S Akira
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

4.  The hyperbaric oxygen preconditioning-induced brain protection is mediated by a reduction of early apoptosis after transient global cerebral ischemia.

Authors:  Robert P Ostrowski; Gerhart Graupner; Elena Titova; Jennifer Zhang; Jeffrey Chiu; Neal Dach; Dalia Corleone; Jiping Tang; John H Zhang
Journal:  Neurobiol Dis       Date:  2007-07-28       Impact factor: 5.996

5.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

6.  Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome.

Authors:  Giuseppe Malleo; Emanuela Mazzon; Tiziana Genovese; Rosanna Di Paola; Carmelo Muià; Rocco Caminiti; Emanuela Esposito; Paolo Di Bella; Salvatore Cuzzocrea
Journal:  Shock       Date:  2008-05       Impact factor: 3.454

7.  Role of hyperbaric oxygen exposure in reduction of lipid peroxidation and in multiple organ failure induced by zymosan administration in the rat.

Authors:  S Cuzzocrea; F Imperatore; G Costantino; C Luongo; E Mazzon; M A Scafuro; G Mangoni; A P Caputi; F Rossi; A Filippelli
Journal:  Shock       Date:  2000-03       Impact factor: 3.454

8.  Hyperbaric oxygen therapy prevents vascular derangement during zymosan-induced multiple-organ-failure syndrome.

Authors:  Francesco Imperatore; Salvatore Cuzzocrea; Carlo Luongo; Giovanni Liguori; Antonella Scafuro; Antonella De Angelis; Francesco Rossi; Achille P Caputi; Amelia Filippelli
Journal:  Intensive Care Med       Date:  2004-02-12       Impact factor: 17.440

9.  Effects of calpain inhibitor I on multiple organ failure induced by zymosan in the rat.

Authors:  Salvatore Cuzzocrea; Prabal K Chatterjee; Emanuela Mazzon; Ivana Serraino; Laura Dugo; Tommaso Centorrino; Alberto Barbera; Antonio Ciccolo; Francesco Fulia; Michelle C McDonald; Achille P Caputi; Christoph Thiemermann
Journal:  Crit Care Med       Date:  2002-10       Impact factor: 7.598

10.  Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation.

Authors:  Simona Zarini; Miguel A Gijón; Aaron E Ransome; Robert C Murphy; Angelo Sala
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-04       Impact factor: 11.205

View more
  14 in total

1.  Hyperbaric oxygen therapy in necrotising soft tissue infections: a study of patients in the United States Nationwide Inpatient Sample.

Authors:  Chai R Soh; Ricardo Pietrobon; John J Freiberger; Sophia T Chew; Dimple Rajgor; Mihir Gandhi; Jatin Shah; Richard E Moon
Journal:  Intensive Care Med       Date:  2012-04-20       Impact factor: 17.440

2.  Effects of hyperbaric oxygen on glucose-regulated protein 78 and c-Jun N-terminal kinase expression after spinal cord injury in rats.

Authors:  Xuehua Liu; Chunsheng Li; Fang Liang; Yong Wang; Zhuo Li; Jing Yang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Hyperbaric oxygen preconditioning protects skin from UV-A damage.

Authors:  Ashley M Fuller; Charles Giardina; Lawrence E Hightower; George A Perdrizet; Cassandra A Tierney
Journal:  Cell Stress Chaperones       Date:  2012-08-03       Impact factor: 3.667

4.  Visit to intensive care of 2050.

Authors:  Sharon Einav; Michael O'Connor; Luis Omar Chavez
Journal:  Intensive Care Med       Date:  2016-08-31       Impact factor: 17.440

5.  The relationship between N-acetylcysteine, hyperbaric oxygen, and inflammation in a rat model of acetaminophen-induced nephrotoxicity.

Authors:  Hakan Cermik; Mine Yavuz Taslipinar; Ibrahim Aydin; Mehmet Agilli; Fevzi Nuri Aydin; Fatma Ucar; Bilal Firat Alp; Mehmet Toygar; Esin Ozkan; Ertan Altayli; Tuncer Cayci
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

Review 6.  Hyperbaric oxygen influences chronic wound healing - a cellular level review.

Authors:  J Růžička; J Dejmek; L Bolek; J Beneš; J Kuncová
Journal:  Physiol Res       Date:  2021-12-31       Impact factor: 1.881

7.  Protective effects of hyperbaric oxygen treatment against spinal cord injury in rats via toll-like receptor 2/nuclear factor-κB signaling.

Authors:  Jiewen Tan; Fang Zhang; Fang Liang; Yong Wang; Zhuo Li; Jing Yang; Xuehua Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 8.  The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review.

Authors:  Matteo Paganini; Gerardo Bosco; Filippo A G Perozzo; Eva Kohlscheen; Regina Sonda; Franco Bassetto; Giacomo Garetto; Enrico M Camporesi; Stephen R Thom
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  Focused ultrasound ablation of a large canine oral tumor achieves efficient tumor remission: a case report.

Authors:  Ashish Ranjan; Deepan Kishore; Harshini Ashar; Tina Neel; Akansha Singh; Sunil More
Journal:  Int J Hyperthermia       Date:  2021       Impact factor: 3.914

10.  Year in review in Intensive Care Medicine 2011: I. Nephrology, epidemiology, nutrition and therapeutics, neurology, ethical and legal issues, experimentals.

Authors:  Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2012-01-04       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.